Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.

Yingling ZuRuirui GuiZhen LiJuan WangPei LiYing LiuXiaofeng DongJian Zhou

Published in: Therapeutic advances in hematology (2024)

Our data suggest that vedolizumab is expected to ameliorate SR GI late aGVHD. Further data on the treatment timing, efficacy, and safety of vedolizumab are warranted in prospective clinical trials.

Keyphrases

clinical trial
ulcerative colitis
patients with inflammatory bowel disease
electronic health record
big data
combination therapy
machine learning
replacement therapy
artificial intelligence
extracorporeal membrane oxygenation
smoking cessation